{"version":"1.0","provider_name":"Frezza Partners","provider_url":"https:\/\/frezzapartners.com\/en\/","author_name":"Frezza Partners","author_url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/","title":"Oncologia, in Relay Therapeutics arriva un ex manager AstraZeneca - Frezza Partners","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"oNhVg7SmMB\"><a href=\"https:\/\/frezzapartners.com\/en\/oncologia-relay-therapeutics-accoglie-un-ex-manager-astrazeneca\/\">Oncologia, in Relay Therapeutics arriva un ex manager AstraZeneca<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/frezzapartners.com\/en\/oncologia-relay-therapeutics-accoglie-un-ex-manager-astrazeneca\/embed\/#?secret=oNhVg7SmMB\" width=\"600\" height=\"338\" title=\"&#8220;Oncologia, in Relay Therapeutics arriva un ex manager AstraZeneca&#8221; &#8212; Frezza Partners\" data-secret=\"oNhVg7SmMB\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/frezzapartners.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/05\/pexels-chokniti-khongchum-3082451-scaled.jpg","thumbnail_width":2560,"thumbnail_height":1709,"description":"photo by Chokniti Khongchum \u00a0 Il mese scorso Twitter aveva rivelato, che Charles Fert\u00e9, M.D., Ph.D. di AstraZeneca, direttore senior e capo progetto globale di ricerca e sviluppo in oncologia, stava lasciando la Big Pharma, senza sapere quale sarebbe stata la sua nuova destinazione. Ora lo sappiamo, ed \u00e8 una storia che si \u00e8 gi\u00e0 verificata spesso in passato: un manager che lascia una grande societ\u00e0 globale per il mondo della &#8220;scienza grezza&#8221; delle biotecnologie. Per essere precisi, Fert\u00e9 sta..."}